ReviewNanomedicine (London, England)2025
Advances in selenium-based nanomedicines for cardiovascular disease therapy: mechanisms, current trends, and prospects.
Review in Nanomedicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Amelioration of 5-Fluorouracil-Induced Hepatorenal Toxicity by Epigallocatechin Gallate-Functionalized Selenium Nanoparticles: A Multi-Targeted Protective Approach.International journal of molecular sciences · 2026Article
- Seasonal regulation of selenium biofortification in tea through Se-rich organic fertilizer application.Frontiers in plant science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular disorders are among the leading causes of death globally, posing significant health and economic challenges. Selenium nanoparticles have emerged as promising carriers for targeted therapy due to their unique antioxidant, anti-inflammatory, and cardioprotective properties. This review summarizes the therapeutic potential of selenium nanoparticles in managing cardiovascular diseases, as well as their applications in related conditions such as rheumatoid arthritis, asthma, inflammatory bowel disease, psoriasis, cancer, diabetes, nonalcoholic fatty liver disease, and infectious diseases. A comprehensive literature search was conducted using databases including PubMed, Scopus, and Web of Science, covering studies published between 2010 and 2024. Key challenges addressed include target identification for selenium nanoparticles and functionalization strategies to enhance their stability and targeted delivery while minimizing off-target effects. We also discuss recent advances in nanoparticle functionalization and their integration into biocompatible scaffolds. Core findings highlight selenium nanoparticles as versatile nanoplatforms with significant clinical translation potential for cardiovascular therapy. Further research is needed to optimize their design and fully elucidate their mechanisms of action.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.